CLINICAL TRIAL / NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Interventional
- Active
- NCT06756035
Contact Information
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.